Plain-English translation of NCT04986579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing the Paxman Scalp Cooling System, a device designed to prevent hair loss during chemotherapy treatment for metastatic breast cancer. The system uses cooling technology applied to the scalp during chemotherapy infusions. While the FDA has already approved this device for preventing hair loss with some chemotherapy drugs, this study is specifically looking at whether it works well with three particular medications: , , or .
Hair loss is a common and distressing side effect of chemotherapy that can affect patients' quality of life and confidence. Although the scalp cooling device is already approved by the FDA, it hasn't been formally studied with these three newer chemotherapy medications, so doctors want to know if it works just as well with them.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive your standard chemotherapy treatment and use the scalp cooling device on specific days during each 21-day treatment cycle (either on days 1, 8, and 21, or days 1 and 21, depending on which medication you're receiving). You'll have photographs taken, complete questionnaires about hair loss, and attend follow-up visits for 2–4 weeks after your chemotherapy ends. The total length of participation depends on how many cycles your doctor recommends, which could be up to 2 years.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States